Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Newbury Pharmaceuticals
Lund, Skåne, Swedennewburypharma.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Commercial
01
Overview
Newbury Pharmaceuticals has transitioned from portfolio build-up to commercial phase. As of late 2022/early 2023:
- Five products received regulatory approval in Scandinavia.
- Two products launched with national tenders won.
- Ongoing launches expected as more approvals are secured. The company focuses on providing cost-effective alternatives for specialty indications where branded drugs dominate the market
- Therapeutic areas
- OncologyRare DiseasesNeurology
- Modalities
- Small molecules (primarily generics and specialty drugs)
- Industry
- Biotech
02
Partnerships
Strategic partnerships for licensing/distribution with international pharma companies to bring branded generics/specialty medicines to the Nordic market. Specific partners not named publicly.
Beyond the preview
Go deeper on Newbury Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Newbury Pharmaceuticals.